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Rationale: Exacerbations of COPD are managed differently, but whether treatment of one 
exacerbation predicts the likelihood of subsequent events is unknown.
Objective: We examined whether the treatment given for exacerbations predicted subsequent 
outcomes.
Methods: This was a post-hoc analysis of 17,135 patients with COPD from TIOtropium Safety 
and Performance In Respimat® (TIOSPIR®). Patients treated with tiotropium with one or more 
moderate to severe exacerbations on study were analyzed using descriptive statistics, logistic 
and Cox regression analysis, and Kaplan–Meier plots.
Results: Of 8,061 patients with moderate to severe exacerbation(s), demographics were similar 
across patients with exacerbations treated with antibiotics and/or steroids or hospitalization. 
Exacerbations treated with systemic corticosteroids alone or in combination with antibiotics 
had the highest risk of subsequent exacerbation (HR: 1.21, P=0.0004 and HR: 1.33, P,0.0001, 
respectively), and a greater risk of having a hospitalized (severe) exacerbation (HR: 1.59 and 
1.63, P,0.0001, respectively) or death (HR: 1.50, P=0.0059 and HR: 1.47, P=0.0002, respec-
tively) compared with exacerbations treated with antibiotics alone. Initial hospitalization led to 
the highest risk of subsequent hospitalization (all-cause or COPD related [severe exacerbation], 
HR: 3.35 and 4.31, P,0.0001, respectively) or death (all-cause or COPD related, HR: 3.53 and 
5.54, P,0.0001, respectively) versus antibiotics alone.
Conclusion: These data indicate that the way exacerbations are treated initially is a useful 
guide to the patient’s subsequent clinical course. Factors that clinicians consider when making 
treatment choices require further clarification.
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Introduction
The pharmacological treatment of acute exacerbations of COPD has changed relatively 
little over the last two decades. Oral corticosteroids are used to shorten the length of the 
exacerbation,1,2 reduce the risk of subsequent relapse,3 and are as effective when given 
for 5 as for 14 days.4 Antibiotics, which are given when patients meet the Anthonisen 
criteria for infected sputum,5 promote microbiological cure6 and possibly reduce the 
risk of relapse,7 both of which are important considerations for hospitalized patients.8 
The prognosis is worse when hospitalization is needed than when patients can be cared 
for at home.9 These operational definitions of exacerbation have been widely adopted 
in clinical trials and by regulators.
While the treatment provided is likely to reflect physicians’ best efforts at pheno-
typing the exacerbation based on the information available to them, more informa-
tion is needed about what influences clinicians’ or patients’ treatment choices for the 
management of an exacerbation. The results of randomized, controlled trials show that 
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the main effect of including an anti-inflammatory agent like 
an inhaled corticosteroid (ICS) in the maintenance treatment 
regimen is a reduction in the number of exacerbations treated 
with oral corticosteroids,10,11 even when the physician has 
been blinded to the preventive therapy being taken. Whether 
the chosen treatment regimen identifies patients at risk of 
subsequent relapse, and/or the occurrence of more serious 
events, remains unclear.
We have investigated the relationship between the treat-
ment of exacerbations and subsequent patient outcomes 
using data collected as part of the TIOtropium Safety and 
Performance In Respimat® (TIOSPIR®) trial,12,13 with the 
largest number of randomized patients with COPD followed 
in a long-term randomized trial to date. TIOSPIR data are 
helpful as all participants received the long-acting mus-
carinic antagonist (LAMA) tiotropium, a therapy recom-
mended for maintenance treatment in all Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) stages of 
COPD.14 As there were no differences in outcomes between 
the treatment arms, we have pooled the data and examined 
whether there were differences in the clinical characteristics 
of patients according to the treatment received for their first 
(index) acute on-treatment exacerbation, and whether the 
subsequent clinical course differed according to the treatment 
choices made during the management of this initial event.
Methods
study design
TIOSPIR was a large (N=17,135), long-term (2–3 years fol-
low-up), randomized, double-blind, double-dummy, parallel- 
group, event-driven trial in patients with COPD. The trial 
design and methodology have been published previously.12,13 
The trial was performed in accordance with the provisions 
of the Declaration of Helsinki, and the study protocol and 
procedures were approved by relevant institutional review 
boards and ethics committees (independent ethics commit-
tee Johns Hopkins Medicine Institutional Review Board, 
Baltimore, MD, USA). All the patients provided written 
informed consent.
study population
Participants in TIOSPIR had a diagnosis of COPD with a 
post-bronchodilator FEV
1
 #70% predicted and an FEV
1
/FVC 
ratio #0.70 were aged $40 years, with a smoking history 
of $10 pack-years. All COPD medications were allowed 
except other inhaled anticholinergic agents and systemic 
corticosteroid medication at unstable (,6 weeks) or high 
(chronic; equivalent of 10 mg/day prednisolone) doses. 
Patients whose first on-treatment exacerbation was moderate 
or severe were included in the analysis. Patients without 
exacerbations, or whose first exacerbation was mild, were 
excluded.
assessments
At randomization, patients received once-daily tiotropium 
(Spiriva® [Boehringer Ingelheim, Ingelheim am Rhein, 
Germany]) via Respimat 5 μg (two inhalations of 2.5 μg), 
Respimat 2.5 μg (two inhalations of 1.25 μg), or HandiHaler® 
18 μg, and the parallel HandiHaler or Respimat placebo. 
They were reviewed at Weeks 0, 6, and 12, and then every 
12 weeks. At each visit, data about symptomatic exacerba-
tions, and how these were treated, were collected. An inde-
pendent mortality adjudication committee attributed the 
cause of each death. 
Exacerbations were defined as the worsening of two or 
more major respiratory symptoms (dyspnea, cough, sputum, 
chest tightness, or wheezing) for $3 days and requiring 
specified treatment changes. Following current practice, 
the severity of exacerbations was defined by the type of 
treatment received: moderate exacerbations required a pre-
scription for antibiotics, systemic corticosteroids, or both 
(with no hospitalization) and severe exacerbations required 
hospitalization (due to COPD). While hospitalized patients 
commonly received antibiotics and/or corticosteroids, no 
therapy details were available; these events were analyzed 
separately (all groups are mutually exclusive).
The onset of exacerbation was defined as the onset of the 
first reported symptom; the end of exacerbation was decided 
by the investigator, based on clinical judgment. A period of at 
least 7 days between exacerbations was required to consider 
them as two separate exacerbations.
statistical analysis
Post-hoc exploratory analyses on pooled treatment arms were 
performed to examine the relationship between the treatment 
choice for the index exacerbation and subsequent outcomes 
(exacerbation, hospitalization, death, or discontinuation 
including death).
HRs and 95% CIs were calculated using a Cox propor-
tional hazard regression model, with factors for treatment 
received for index exacerbation, ICS use at baseline, and 
exacerbation history. Negative binomial regression models 
with the same factors were used to estimate the annual rates 
and rate ratios.
To examine the immediate effect of the index exacerbation, 
we calculated the odds ratios for events within the first 60 days 
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at risk following the index exacerbation, based on logistic 
regression, with factors for treatment received for index exac-
erbation, ICS use at baseline, and exacerbation history. 
The day after the start of their index exacerbation, patients 
were considered to be at risk of adverse events requiring or 
prolonging hospitalization (subsequent hospitalization), or 
leading to death (including death due to COPD), or discon-
tinuation. Time at risk of subsequent exacerbation started 
after the end of the index exacerbation.
Results
study population
On-treatment exacerbations were reported in 8,342 patients. 
Of these, 8,061 (96.6%) patients who received antibiotics 
and/or systemic corticosteroids (moderate exacerbation), 
or who were hospitalized (severe exacerbation) for their 
index exacerbation, were included in the analysis. There 
were no differences in treatment received for the first on-
treatment exacerbation between different regions of the 
world, except for slightly more patients from Asia being 
initially hospitalized.
Baseline characteristics by treatment for the first moderate 
or severe exacerbation are shown in Table 1. Most patients 
were male (67.8%), mean age was 65 years, mean body mass 
index (BMI) was 26.1 kg/m2, and mean smoking history 
was 45 pack-years. There were a higher proportion of patients 
who were underweight in the group that was hospitalized 
for their index exacerbation than in the groups that received 
antibiotics or steroids. Patients who were hospitalized for 
their index exacerbation had worse post-bronchodilator 
FEV
1
 percent predicted at baseline than those who received 
antibiotics only (41.7% and 48.9%, respectively). There-
fore, patients whose index exacerbation was treated with 
antibiotics only were more likely to be in GOLD Stage I/II 
(50.1%), while patients receiving systemic corticosteroids 
alone or in combination with antibiotics, or who were hos-
pitalized for their index exacerbation, were predominantly in 
GOLD Stage III (43.7%, 45.0%, and 47.9%, respectively). 
The mean duration of index exacerbations ranged from 
15.6 to 21.1 days (Table 2).
The use of concomitant cardiovascular medication was 
similar between groups (52.2% overall); however, the pres-
ence of a history of cardiac disorders at baseline varied by 
treatment received for the index exacerbation, ranging from 
22.4% of patients treated with systemic corticosteroids 
only to 32.6% of patients who required hospitalization. 
Patients with a history of heart failure appeared to be more 
likely to be hospitalized for an exacerbation than to receive 
antibiotic/corticosteroid treatment. Overall, 94.5% of patients 
were taking respiratory medication at study entry, 36.3% 
of whom received triple therapy (ICS/LAMA/long-acting 
β
2
-agonist [LABA]), and 23.0% LABA/ICS (Table 1).
The median time on study treatment after the index exac-
erbation did not differ according to the treatment received for 
the index exacerbation (521–551 days) except for patients 
who were hospitalized; these patients spent a shorter time on 
treatment (412 days) following the initial event (Table 2). 
Index exacerbation(s)
nonhospitalized exacerbations
The frequency of subsequent exacerbations varied by 
treatment received for the index exacerbation. The annual 
exacerbation rate for patients with antibiotics only (0.79) 
was lower than that for those treated with systemic cor-
ticosteroids alone (0.95) or in combination with antibiot-
ics (1.04; Table 2). Accordingly, the time to subsequent 
exacerbations was shorter (greater risk) for patients treated 
with systemic corticosteroids only (HR: 1.21 [95% CI: 
1.09–1.34]) or antibiotics and systemic corticosteroids (HR: 
1.33 [95% CI: 1.24–1.43]) versus those treated with antibiot-
ics only (Figure 1; Table S1).
When looking at exacerbations occurring within 60 days 
of the end of the index exacerbation, 14.7% of patients treated 
with systemic corticosteroids only and 16.3% with antibiotics 
and corticosteroids experienced another exacerbation versus 
11.6% and 12.2% for those whose initial event required 
hospitalization or antibiotics only (Table 3). Kaplan–Meier 
analysis showed that patients who received antibiotics and 
systemic corticosteroids for their index exacerbation had the 
highest estimated probability of a subsequent exacerbation 
(Figure 2A).
exacerbations requiring hospitalization
Patients who experienced severe index exacerbation (hos-
pitalized) had a higher annual rate of subsequent hospital-
ization due to COPD than patients who experienced a less 
severe initial event (Table 2). Consequently, patients who 
experienced a severe index exacerbation had a higher risk of 
a subsequent hospitalized exacerbation than patients with a 
moderate index exacerbation who received antibiotics only 
(HR: 4.31 [95% CI: 3.76–4.95]; Figure 1; Table S1). Patients 
who required hospitalization for their initial event were also 
at higher risk of a subsequent severe exacerbation within 
60 days than those who received antibiotics, corticosteroids, 
or a combination thereof.
Patients who initially required hospitalization had a 
similar rate of subsequent exacerbation to those treated with 
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Table 1 Patient demographics and baseline characteristics
Characteristic Total study 
population, 
N=8,061
Index on-treatment exacerbation
Moderate Severe 
(requiring 
hospitalization), 
N=1,490
Treated with 
antibiotics 
only, 
N=3,080
Treated with 
systemic 
corticosteroids 
only, N=821
Treated with 
antibiotics 
and systemic 
corticosteroids, 
N=2,670
Males, n (%) 5,463 (67.8) 2,091 (67.9) 564 (68.7) 1,667 (62.4) 1,141 (76.6)
age, years, mean (sD) 65.2 (9.0) 64.7 (8.9) 65.5 (9.2) 65.2 (9.0) 66.2 (9.0)
BMI, kg/m2, mean (sD) 26.1 (5.8) 26.4 (5.6) 25.9 (5.7) 26.2 (5.8) 25.4 (6.1)
BMI category, n (%)
,18.5 kg/m2
18.5 to ,25 kg/m2
25 to ,30 kg/m2
$30 kg/m2
564 (7.0)
3,175 (39.4)
2,537 (31.5)
1,785 (22.1)
178 (5.8)
1,135 (36.9)
1,066 (34.6)
701 (22.8)
52 (6.3)
352 (42.9)
250 (30.5)
167 (20.3)
182 (6.8)
1,020 (38.2)
853 (31.9)
615 (23.0)
152 (10.2)
668 (44.8)
368 (24.7)
302 (20.3)
region, n (%)
euro/africa/aus/nZ
latin america
north america
asia
4,342 (53.9)
539 (6.7)
2,227 (27.6)
953 (11.8)
1,842 (59.8)
168 (5.5)
721 (23.4)
349 (11.3)
427 (52.0)
82 (10.0)
217 (26.4)
95 (11.6)
1,284 (48.1)
230 (8.6)
958 (35.9)
198 (7.4)
789 (53.0)
59 (4.0)
331 (22.2)
311 (20.9)
Duration of COPD, years, mean (sD) 7.9 (6.2) 7.7 (6.3) 7.9 (6.1) 8.1 (6.2) 7.7 (6.0)
smoking history, pack-years, mean (sD)a 44.7 (25.3) 43.0 (23.7) 45.0 (26.0) 46.1 (26.2) 45.2 (26.3)
no of COPD episodes treated in the last year,  
mean (sD)
1.0 (1.3) 1.0 (1.3) 0.9 (1.3) 1.1 (1.4) 1.1 (1.3)
no of COPD episodes treated in the last year, n (%)a
0
1
2
3
4
$5
3,561 (44.2)
2,437 (30.2)
1,186 (14.7)
512 (6.4)
194 (2.4)
164 (2.0)
1,409 (45.7)
934 (30.3)
435 (14.1)
174 (5.6)
74 (2.4)
51 (1.7)
407 (49.6)
229 (27.9)
109 (13.3)
43 (5.2)
16 (1.9)
16 (1.9)
1,172 (43.9)
772 (28.9)
404 (15.1)
185 (6.9)
73 (2.7)
62 (2.3)
573 (38.5)
502 (33.7)
238 (16.0)
110 (7.4)
31 (2.1)
35 (2.3)
Postbronchodilator spirometry, mean (sD)a
FeV1, l
FeV1, % predicted
FVC, l
ratio of FeV1 to FVC
1.265 (0.459)
46.4 (13.9)
2.649 (0.832)
0.484 (0.115)
1.354 (0.469)
48.9 (13.7)
2.758 (0.842)
0.497 (0.113)
1.248 (0.450)
45.7 (13.8)
2.634 (0.854)
0.482 (0.121)
1.249 (0.446)
46.3 (13.6)
2.624 (0.812)
0.482 (0.115)
1.119 (0.420)
41.7 (13.7)
2.477 (0.800)
0.459 (0.114)
gOlD stage, n (%)a
I/II
III
IV
Cardiac history
Previous cardiac arrhythmia, n (%)
3,410 (42.3)
3,478 (43.1) 
1,074 (13.3) 
2,171 (26.9)
909 (11.3)
1,543 (50.1)
1,205 (39.1)
292 (9.5) 
825 (26.8)
348 (11.3)
327 (39.8) 
359 (43.7)
123 (15.0)
184 (22.4)
83 (10.1)
1,097 (41.1)
1,201 (45.0)
337 (12.6)
677 (25.4)
298 (11.2)
443 (29.7)
713 (47.9)
322 (21.6)
485 (32.6)
180 (12.1)
Previous MI, n (%) 515 (6.4) 181 (5.9) 44 (5.4) 181 (6.8) 109 (7.3)
Previous stroke, n (%) 177 (2.2) 64 (2.1) 18 (2.2) 53 (2.0) 42 (2.8)
Previous IhD or CaD, n (%) 1,225 (15.2) 483 (15.7) 106 (12.9) 354 (13.3) 282 (18.9)
history of heart failure, n (%)a
none
Class I
Class II
Class III
Class IV
7,453 (92.5)
222 (2.8)
321 (4.0)
55 (0.7)
3 (0.0)
2,856 (92.7)
82 (2.7)
120 (3.9)
17 (0.6)
1 (0.0)
779 (94.9)
13 (1.6)
25 (3.0)
3 (0.4)
1 (0.1)
2,530 (94.8)
57 (2.1)
65 (2.4)
16 (0.6)
0 (0.0)
1,288 (86.4)
70 (4.7)
111 (7.4)
19 (1.3)
1 (0.1)
Taking CV medication, n (%) 4,204 (52.2) 1,610 (52.3) 421 (51.3) 1,416 (53.0) 757 (50.8)
Taking respiratory medication, n (%)a 7,620 (94.5) 2,853 (92.6) 793 (96.6) 2,561 (95.9) 1,413 (94.8)
ICs only
laBa only
laMa only
laBa+ICs only 
ICs+laBa+laMa
438 (5.4)
355 (4.4)
741 (9.2)
1,852 (23.0)
2,924 (36.3)
134 (4.4)
159 (5.2)
323 (10.5)
693 (22.5)
1,041 (33.8)
52 (6.3)
34 (4.1)
79 (9.6)
185 (22.5)
292 (35.6)
159 (6.0)
104 (3.9)
216 (8.1)
620 (23.2)
1,038 (38.9)
93 (6.2)
58 (3.9)
123 (8.3)
354 (23.8)
553 (37.1)
Notes: Percentages shown are “column” percentages. aPatients with missing data were excluded.
Abbreviations: aus, australia; BMI, body mass index; CaD, coronary artery disease; CV, cardiovascular; euro, europe; gOlD, global Initiative for Chronic Obstructive 
lung Disease; ICs, inhaled corticosteroid; IhD, ischemic heart disease; laBa, long-acting β2-agonist; laMa, long-acting muscarinic antagonist; MI, myocardial infarction; nZ, 
new Zealand.
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Table 2 Median time to, and annual rate of event by, treatment for index moderate or severe exacerbation, adjusted for inhaled 
corticosteroid use and exacerbation history
Subsequent event Index on-treatment exacerbation
Moderate Severe
(requiring 
hospitalization)
Treated with 
antibiotics 
only
Treated with 
systemic 
corticosteroids 
only
Treated with 
antibiotics 
and systemic 
corticosteroids
Duration of index exacerbation, days (sD) 15.6 (20.1) 19.2 (28.5) 21.1 (33.7) 19.6 (23.2)
Total time on study treatment after the start of index 
exacerbation, days, median
551 521 550 412
no of patients in the exacerbation analysis n=3,028 n=791 n=2,577 n=1,359
Moderate to severe exacerbation, n (%) 1,631 (53.9) 450 (56.9) 1,610 (62.5) 700 (51.5)
Time to subsequent exacerbation, days, median (Q1, Q3) 376 (128, 902) 282 (111, 777) 261 (92, 645) 341 (124, 804)
annual rate (95% CI) 0.79 (0.75–0.83) 0.95 (0.88–1.03) 1.04 (0.99–1.09) 0.86 (0.80–0.92)
severe exacerbation, n (%) 355 (11.7) 135 (17.1) 478 (18.5) 483 (35.5)
annual rate (95% CI) 0.10 (0.09–0.11) 0.16 (0.13–0.19) 0.17 (0.16–0.19) 0.46 (0.41–0.52)
no of patients in the hospitalization, death, and 
discontinuation analysis
n=3,070 n=820 n=2,660 n=1,486
hospitalization (all-cause), n (%) 772 (25.1) 242 (29.5) 838 (31.5) 758 (51.0)
annual rate (95% CI) 0.28 (0.26–0.30) 0.36 (0.32–0.42) 0.39 (0.36–0.42) 0.98 (0.89–1.07)
Death (all-cause), n (%) 164 (5.3) 64 (7.8) 209 (7.9) 240 (16.2)
Death due to COPD, n (%) 45 (1.5) 26 (3.2) 85 (3.2) 106 (7.1)
Discontinuation, n (%) 435 (14.2) 162 (19.8) 509 (19.1) 434 (29.2)
Notes: Percentages shown are “column” percentages. Time at risk of subsequent exacerbation started the day after the end of the first exacerbation and ended at treatment 
stop. Time at risk of subsequent hospitalization, discontinuation, or death started the day after the start of the first exacerbation and ended at treatment stop +30 days 
(or death) (for hospitalization), treatment stop (for discontinuation), or at last known date alive or death (for death).
Abbreviation: Q, quartile.
Figure 1 Forest plot showing the risk of subsequent event by treatment for index exacerbation versus antibiotics only.
Notes: hazard ratios for the time at risk of subsequent exacerbation were adjusted for inhaled corticosteroid use at baseline and exacerbation in the year prior to study. 
Time at risk of subsequent exacerbation started the day after the end of the first exacerbation and ended at treatment stop. Time at risk of subsequent hospitalization, 
discontinuation, or death started the day after the start of the first exacerbation and ended at treatment stop +30 days (or death) (for hospitalization), treatment stop 
(for discontinuation), or at last known date alive or death (for death).
Moderate to severe exacerbation
Severe exacerbation
Hospitalization (all-cause)
Discontinuation
Index
exacerbation
treated with:
Index
exacerbation
treated with:
Index
exacerbation
treated with:
Index
exacerbation
treated with:
Index
exacerbation
treated with:
Index
exacerbation
treated with:
1.46 (1.22–1.75), P<0.0001
1.38 (1.21–1.56), P<0.0001
2.52 (2.21–2.88), P<0.0001
2.23 (1.38–3.62), P=0.0011
2.15 (1.50–3.09), P<0.0001
5.54 (3.91–7.86), P<0.0001
1.50 (1.12–2.00), P=0.0059
1.47 (1.20–1.80), P=0.0002
3.53 (2.90–4.31), P<0.0001
1.29 (1.11–1.49), P=0.0007
1.32 (1.20–1.45), P<0.0001
3.35 (3.03–3.70), P<0.0001
1.59 (1.30–1.94), P<0.0001
1.63 (1.42–1.87), P<0.0001
4.31 (3.76–4.95), P<0.0001
1.21 (1.09–1.34), P=0.0004
1.33 (1.24–1.43), P<0.0001
1.06 (0.97–1.16), P=0.18
Systemic corticosteroids only
Antibiotics+systemic corticosteroids
Hospitalization
Systemic corticosteroids only
Antibiotics+systemic corticosteroids
Hospitalization
Systemic corticosteroids only
Antibiotics+systemic corticosteroids
Hospitalization
Systemic corticosteroids only
Antibiotics+systemic corticosteroids
Hospitalization
Systemic corticosteroids only
Antibiotics+systemic corticosteroids
Hospitalization
Systemic corticosteroids only
Antibiotics+systemic corticosteroids
Hospitalization
Death due to COPD
Death (all-cause)
0.9 1 5 10
Hazard ratio (95% CI) versus treatment
with antibiotics only
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Table 3 logistic regression analysis: relationship between index exacerbation severity and subsequent exacerbation, hospitalization, 
or death within 60 days following first on-treatment exacerbation
Subsequent event Index on-treatment exacerbation
Moderate Severe 
(requiring 
hospitalization)
Treated with 
antibiotics 
only
Treated with 
systemic 
corticosteroids 
only
Treated with 
antibiotics 
and systemic 
corticosteroids
no of patients in the exacerbation 
analysis
n=3,028 n=791 n=2,577 n=1,359
Moderate to severe exacerbation, n (%)
Or (95% CI)
369 (12.2)
–
116 (14.7)
1.26 (1.00–1.57)
420 (16.3)
1.37 (1.18–1.59)
158 (11.6)
0.90 (0.74–1.10)
severe exacerbation, n (%)
Or (95% CI)
49 (1.6)
–
22 (2.8)
1.75 (1.03–2.87)
71 (2.8)
1.67 (1.16–2.42)
106 (7.8)
4.91 (3.49–6.99)
no of patients in the hospitalization, 
death, and discontinuation analysis
n=3,070 n=820 n=2,660 n=1,486
hospitalization (all-cause), n (%)
Or (95% CI)
107 (3.5)
–
40 (4.9)
1.41 (0.96–2.03)
135 (5.1)
1.46 (1.13–1.89)
283 (19.0)
6.44 (5.12–8.15)
Death (all-cause), n (%)
Or (95% CI)
10 (0.3)
–
7 (0.9)
2.72 (0.98–7.10)
21 (0.8)
2.47 (1.19–5.49)
61 (4.1)
12.97 (6.93–27.02)
Discontinuation, n (%)
Or (95% CI)
66 (2.2)
–
40 (4.9)
2.33 (1.55–3.46)
102 (3.8)
1.82 (1.33–2.50)
169 (11.4)
5.85 (4.39–7.88)
Notes: Percentages shown are “column” percentages. OR was calculated for subsequent events within 60 days started either after the onset of the first exacerbation 
(not leading to discontinuation) (for subsequent hospitalization, death, and discontinuation) or after the end of the first exacerbation (not leading to discontinuation) 
(for subsequent exacerbation). Or was calculated for patients treated with antibiotics only and adjusted for inhaled corticosteroid use at baseline and exacerbation in the 
year prior to study.
Abbreviation: Or, odds ratio.
antibiotics only (HR: 1.06 [95% CI: 0.97–1.16]) and a lower 
risk of subsequent exacerbation versus patients treated with 
antibiotics and systemic corticosteroids (HR: 1.25 [95% CI: 
1.15–1.37]; Table S1).
subsequent hospitalization (all-cause)
Annual rates for (all-cause) hospitalizations followed the 
same pattern as those observed for hospitalizations due 
to COPD, and these were lowest in patients who were treated 
Figure 2 (Continued)
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with antibiotics only and highest in patients initially hospital-
ized for their index exacerbation (Table 2). This was reflected 
in a shorter time to (greater risk of) subsequent hospitalization 
for patients who were initially hospitalized versus antibiotics 
only (HR: 3.35 [95% CI: 3.03–3.70]) compared with patients 
who received systemic corticosteroids (HR: 1.29 [95% CI: 
1.11–1.49]), or antibiotics and corticosteroids (HR: 1.32 
[95% CI: 1.20–1.45]; Figure 1; Table S1). Similarly, patients 
hospitalized for their index exacerbation were more than 
four times as likely to experience an adverse event requiring 
hospitalization within 60 days of the onset of the index 
exacerbation as patients who experienced a less severe initial 
event (Table 3). Kaplan–Meier analysis showed that initially 
hospitalized patients were at the highest risk of a subsequent 
hospitalization compared with patients who were treated with 
antibiotics and/or steroids (Figure 2B).
subsequent death (all-cause)
The percentage of patients who died was twice as high for 
patients whose index exacerbation required hospitalization 
Figure 2 Time to (A) subsequent exacerbation, (B) hospitalization (all-cause) or (C) death (all-cause), by severity of first exacerbation on treatment.
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than for those with less severe index exacerbations. There-
fore, hospitalization for index exacerbation was an important 
risk factor for subsequent death (all-cause; HR: 3.53 [95% CI: 
2.90–4.31]), in particular for death due to COPD (HR: 5.54 
[95% CI: 3.91–7.86]; Figure 1; Table S1) versus patients 
treated with antibiotics only. Patients who received systemic 
corticosteroids only (HR: 1.50 [95% CI: 1.12–2.00]) or in 
combination with antibiotics (HR: 1.47 [95% CI: 1.20–1.80]) 
were nevertheless also at a higher risk of subsequent all-
cause death compared with patients treated with antibiotics 
only. In the 60 days following the onset of the initial event, 
patients initially hospitalized were four times more likely 
to die than patients who received antibiotics only, systemic 
corticosteroids only, or the combination (Table 3). These 
results were confirmed by Kaplan–Meier analysis in which 
the estimated probability of subsequent death was highest 
in patients initially hospitalized (Figure 2C).
subsequent discontinuation
A total of 1,540 patients (19.1%) discontinued prematurely 
from the study (for any reason including death and at any 
time) following the onset of their index exacerbation. Patients 
who were hospitalized (severe exacerbation) were most likely 
to discontinue (29.2%); patients receiving antibiotics only 
discontinued the least (14.2%; Table 2). The highest risk of 
premature discontinuation versus patients treated with anti-
biotics only was observed in patients who initially required 
hospitalization (HR: 2.52 [95% CI: 2.21–2.88]), followed 
by patients who were treated with systemic corticosteroids 
(HR: 1.46 [95% CI: 1.22–1.75]), or antibiotics and corticos-
teroids (HR: 1.38 [95% CI: 1.21–1.56]; Figure 1; Table S1). 
Within the first 60 days of onset of the index exacerbation, 
the increased risk of discontinuation in patients initially 
hospitalized (11.4%) was more pronounced than in those 
treated with corticosteroids only (4.9%), with antibiotics 
and corticosteroids (3.8%), or with antibiotics only (2.2%) 
for their index exacerbation (Table 3). 
Discussion
In this retrospective analysis of the TIOSPIR dataset, we 
found that patients with exacerbations who were treated with 
systemic corticosteroids alone, or together with antibiotics, 
exacerbated sooner and more frequently than those treated 
with antibiotics alone, and that an initial hospitalization was 
a powerful predictor of subsequent hospitalization, mortality, 
and premature discontinuation. These findings held true 
even after adjustment for prior ICS use and exacerbation 
history. While we do not suggest that these findings indicate 
that lesser treatment benefits the patient, we do believe that 
the information is of clinical interest both to the analysis of 
COPD trials and to future clinical management.
Time to first COPD exacerbation in the TIOSPIR study 
was a prespecified outcome, but no specific instructions 
were given about how exacerbations should be managed. 
Despite this, and the many healthcare systems that contrib-
uted patients to this study, there were clear differences in the 
treatments given for the first recorded exacerbation (index 
exacerbation) after randomization. It remains unclear, how-
ever, whether geographic and healthcare settings may also 
influence exacerbation outcomes (eg, in Asia, more patients 
were hospitalized for their index exacerbation, whereas 
patients in North America were more likely to receive a com-
bination of antibiotics and steroids). On an individual level, 
the reasons for hospitalization of patients can also vary. 
Nonetheless, using a healthcare utilization definition 
to distinguish different exacerbation groups, we saw little 
difference between patient groups in many baseline variables 
such as age, smoking history, and BMI. There were differ-
ences in the degree of spirometric impairment among those 
receiving antibiotics, those for whom systemic corticoster-
oids were added, and those who were hospitalized for their 
first observed exacerbation. Although such differences are 
reflected in the distribution of GOLD stages among treat-
ment groups, GOLD stage per se did not clearly discriminate 
between treatment choices. Thus, 27.2% of GOLD Stage IV 
patients received antibiotics alone, while almost 30% of 
hospitalized patients were in the GOLD Stage I/II subset. 
This confirms earlier observations about the imperfect rela-
tionship between spirometric impairment and hospitalization 
in COPD studies.15 There were no consistent differences in 
either the reported presence of cardiac disease or cardiac 
medication between treatment groups, suggesting that, in 
this population, COPD hospitalization was likely driven by 
respiratory rather than comorbid cardiac factors.
Outcomes for patients who received systemic corticoster-
oids, whether as monotherapy or combined with antibiotics, 
differed from those for patients treated with antibiotics alone. 
Corticosteroid-treated patients experienced more exacerba-
tions that occurred sooner after the index exacerbation and 
were more likely to require hospitalization or be followed by 
death than was the case in the antibiotic monotherapy group. 
However, the addition of antibiotics to the corticosteroid 
was not associated with differences in outcomes, suggesting 
that the decision to prescribe corticosteroids was the marker 
for poorer outcomes. These between-group differences are 
unlikely to reflect differences in baseline severity of COPD 
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and were evident when the analysis was restricted to the 
60-day risk period following the index exacerbation event. 
The decision to offer a different treatment may reflect the 
clinical perception of differences between the events, eg, 
more “severe” episodes require systemic corticosteroid 
therapy. Clearly, the treatment decision is also influenced by 
customary practices of care. However, some preliminary data 
suggest that patients treated with corticosteroids are more 
likely to report breathlessness as their dominant exacerbation 
symptom, whereas patients who receive antibiotics complain 
mainly of cough and sputum production.16 It is not possible 
to determine, however, whether some patients were treated 
inappropriately and whether this may have affected out-
comes; for instance, oral corticosteroids are associated with 
worse outcomes and earlier relapse when used to treat infec-
tive exacerbations.17 Further studies to explore differences in 
exacerbation treatment choice are warranted.
Hospitalization for COPD is a more serious outcome 
and carries a high risk of subsequent death, as noted 
previously.18–21 This increased mortality risk was seen within 
60 days of the index event and increased further during the 
following year. The risk of death compared with that in 
nonhospitalized patients was broadly similar in the 60-day 
and 12-month follow-up periods, suggesting that in general 
the hospitalized patients were intrinsically more likely to die 
rather than the insult associated with hospitalization being 
especially severe. Hospitalized patients were less likely to 
receive antibiotics and/or corticosteroids as outpatients to 
treat their next exacerbation, which could have been because 
either they were much more likely to be hospitalized on the 
next occasion and/or they were more likely to withdraw 
from the study, or to have died before another event could 
occur. These data confirm that hospitalized patients pursue 
a different natural history than nonhospitalized patients, as 
is suggested from database studies;21 this has been acknowl-
edged in the current GOLD classification of risk severity.14
Our analysis has a number of strengths, but also has some 
limitations. TIOSPIR was a large but relatively uncomplicated 
clinical trial with an almost complete ascertainment of mor-
tality, irrespective of study withdrawal. We adjudicated the 
cause of death independently from the trial steering group, but 
did not repeat this exercise for exacerbations, a technically 
daunting process that is recommended by some authorities.22 
Nonetheless, we regularly monitored whether exacerbations 
had occurred, how they had been treated, and their frequency. 
The size of our study allowed us to distinguish differences in 
exacerbation events between patients treated with antibiotics 
and patients receiving systemic corticosteroids alone – groups 
that are often too small to generate separate analyses in other 
studies.11 All participants received tiotropium, and those 
initially taking LABA and/or ICS – agents known to pre-
vent exacerbations23,24 – continued these drugs, with ~60% 
of participants receiving triple therapy during the study. 
However, we found no difference between the exacerbation-
defined treatment groups in maintenance therapy used, 
suggesting that the therapy for the event when it occurred 
was not determined by the treatment already taken regularly 
to manage their COPD. Finally, our data cannot exclude the 
possibility that therapy with systemic corticosteroids led to 
more frequent exacerbations later, resulting from some as 
yet unidentified deleterious effect of this therapy. Although 
this seems unlikely, further studies to elucidate the long-term 
effect of the initial therapy selected appear to be justified. 
We did not specify how an exacerbation should be 
managed, but suggested that the clinician should follow 
their usual practice. This could be interpreted as a study 
weakness; however, we suggest instead that the results are 
consequently more reflective of the real-life clinical situa-
tion, providing key insights into this perspective. Had we 
been able to monitor patients using diary cards, it is likely 
that we would have identified even more events25 and would 
have also been able to study the time course of recovery 
with treatment, an important consideration when assessing 
the risk of relapse.26 Nevertheless, our data relate to clinical 
circumstances under which this more detailed information 
was not available, and therefore, our findings may be more 
directly relevant to understanding exacerbation management 
during routine clinical practice. 
Our data have wide implications. In patients receiving 
recommended treatments known to prevent COPD exac-
erbations, episodes that required systemic corticosteroid 
treatment with or without antibiotics differed from those 
that were treated with antibiotics only. The same is true for 
exacerbations that led to hospitalizations. Hence, therapies 
that reduce the number of corticosteroid-treated episodes 
(with or without antibiotics) and hospitalizations may be 
particularly impactful.27,28 The considerable predictive value 
of our initial hospitalization data suggests that treatment trials 
where cost-effectiveness is a key outcome should recruit such 
patients, as it is in these studies that signals are most readily 
seen, as was the case with the Roflumilast and Exacerbations 
in patients receiving Appropriate Combination Therapy 
(REACT) study.29 Finally, clinicians should be aware that 
the way they choose to treat exacerbations identifies patients 
who are at different risk of future hospitalization and death. 
Greater awareness of this fact could identify patients at the 
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greatest risk of future problems and ensure they are treated 
and monitored accordingly.
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Supplementary material
Table S1 Time to subsequent event adjusted for inhaled corticosteroid use and exacerbation history
Subsequent event Index on-treatment exacerbation
Moderate Severe 
(requiring 
hospitalization)
Treated with 
antibiotics only
Treated with 
systemic 
corticosteroids 
only
Treated with 
antibiotics 
and systemic 
corticosteroids
no of patients in the exacerbation 
analysis 
n=3,028 n=791 n=2,577 n=1,359 
Moderate to severe exacerbation, n (%) 1,631 (53.9) 450 (56.9) 1,610 (62.5) 700 (51.5)
hr versus antibiotics only (95% CI), 
P-value
– 1.21 (1.09–1.34), 
0.0004
1.33 (1.24–1.43), 
,0.0001
1.06 (0.97–1.16), 
0.18
hr versus hospitalized (95% CI), 
P-value
0.94 (0.86–1.03), 
0.18
1.14 (1.01–1.28), 
0.03
1.25 (1.15–1.37), 
,0.0001
–
severe exacerbation, n (%) 355 (11.7) 135 (17.1) 478 (18.5) 483 (35.5)
hr versus antibiotics only (95% CI), 
P-value
– 1.59 (1.30–1.94), 
,0.0001
1.63 (1.42–1.87), 
,0.0001
4.31 (3.76–4.95), 
,0.0001
hr versus hospitalized (95% CI), 
P-value
0.23 (0.20–0.27), 
,0.0001
0.37 (0.31–0.45), 
,0.0001
0.38 (0.33–0.43), 
,0.0001
–
no of patients in the hospitalization, 
death, and discontinuation analysis
n=3,070 n=820 n=2,660 n=1,486
hospitalization (all-cause), n (%) 772 (25.1) 242 (29.5) 838 (31.5) 758 (51.0)
hr versus antibiotics only (95% CI), 
P-value
– 1.29 (1.11–1.49), 
0.0007
1.32 (1.20–1.45), 
,0.0001
3.35 (3.03–3.70), 
,0.0001
hr versus hospitalized (95% CI), 
P-value
0.30 (0.27–0.33), 
,0.0001
0.38 (0.33–0.44), 
,0.0001
0.39 (0.36–0.44), 
,0.0001
–
Death (all-cause), n (%) 164 (5.3) 64 (7.8) 209 (7.9) 240 (16.2)
hr versus antibiotics only (95% CI), 
P-value
– 1.50 (1.12–2.00), 
0.0059
1.47 (1.20–1.80), 
0.0002
3.53 (2.90–4.31), 
,0.0001
hr versus hospitalized (95% CI), 
P-value
0.28 (0.23–0.35), 
,0.0001
0.43 (0.32–0.56), 
,0.0001
0.42 (0.35–0.50), 
,0.0001
–
Death due to COPD, n (%) 45 (1.5) 26 (3.2) 85 (3.2) 106 (7.1)
hr versus antibiotics only (95% CI), 
P-value
– 2.23 (1.38–3.62), 
0.0011
2.15 (1.50–3.09), 
,0.0001
5.54 (3.91–7.86), 
,0.0001
hr versus hospitalized (95% CI), 
P-value
0.18 (0.13–0.26), 
,0.0001
0.40 (0.26–0.62), 
,0.0001
0.39 (0.29–0.52), 
,0.0001
–
Discontinuation, n (%) 435 (14.2) 162 (19.8) 509 (19.1) 434 (29.2)
hr versus antibiotics only (95% CI), 
P-value
– 1.46 (1.22–1.75), 
,0.0001
1.38 (1.21–1.56), 
,0.0001
2.52 (2.21–2.88), 
,0.0001
hr versus hospitalized (95% CI), 
P-value
0.40 (0.35–0.45), 
,0.0001
0.58 (0.48–0.69), 
,0.0001
0.55 (0.48–0.62), 
,0.0001
–
Notes: Time at risk of subsequent exacerbation started the day after the end of the first exacerbation and ended at treatment stop. Time at risk of subsequent hospitalization, 
discontinuation, or death started the day after the start of the first exacerbation and ended at treatment stop +30 days (or death) (for hospitalization), treatment stop 
(for discontinuation), or at last known date alive or death (for death).
